Husson B, Barbe C, Hegazy S, et al. - Researchers conducted this multicentre retrospective descriptive study to assess the real‐life effectiveness of tumour necrosis factor blockers and ustekinumab in palmoplantar pustulosis (PPP) and in acrodermatitis continua of Hallopeau (ACH). This investigation was performed in 19 dermatology departments. The sample consisted of all patients with PPP or ACH seen from 2014 to 2016 who received one of the studied biologics. Among 92 individuals involved, 50 received adalimumab, 44 ustekinumab, 36 etanercept and 31 infliximab. No significant difference was observed in complete clearance rates or duration of treatment among the biological treatments. There was no difference in effectiveness between TNF blockers and ustekinumab and between the three different TNF blockers in real life for PPP or ACH, which showed the heterogeneity of clinical response to pustular psoriasis biologics compared with plaque psoriasis.